RESUMO
Objective To evaluate the efficacy of topicalJinhuang unction combined with oralSangqin mixture forthe patients with moderate to severe acnevulgaris.Methods A total of 72 patients with moderate to severe acne (Pills bury grade 2 or grade 3) were included and divided into a study group and a control group by random number table method, 36 in each group. The patients were treated for 2 months in the study group with topicalJinhuang unction combined with oralSangqin mixture, and in the control group with topical fusidic acid combined with oralSangqin mixture. The number of lesions and the Global Acne GradingSystem (GAGS) score for each patient were obtained and evaluated. The number offollicularPropionibacterium acnes was determined with real-time fluorescence quantitative polymerase chain reaction.Results After treatment, the number of papule (28.69 ± 10.50vs. 36.61 ± 10.10;t=3.262,P=0.002) was significantly less than that in the control group. The pustules was 1(0, 3) and the nodules was 0 (0, 1) in the study group, which were significantly less than those of 3(0, 15) and 0 (0, 4) in the control group (P<0.01). The GAGS scores was 13(6, 24), which was significantly less than those of 20(17, 32) in the control group significantly lower (Z=-6.482,P<0.01). The number reduction rate of follicular Propionibacterium acnes per unit area in the study group were 43.07% (-57.14%, 86.23%), which was significantly higher than that of 12.68% (-34.52%, 51.11%) in the control group (Z=-2.705,P=0.007). Conclusions TopicalJinhuang unction combined with oralSangqin mixture may reduce the damage of the skin, decrease the numbers of papule, pustules and nodules, depressPropionibacterium acnes in patients with moderate to severe acne vulgaris. TopicalJinhuang unction combined with oralSangqin mixture is superior to topical fusidic acid combined with oralSangqin mixture for the treatment of moderate to severe acne vulgaris.
RESUMO
Here, we presented a method to bacterially express the major structural protein L1 of Human Papillomavirus type 18 (HPV18) as soluble form. We found that the purified L1 could self-assemble to virus-like particles (VLPs). Further, we investigated the immunogenicity and the induced level of neutralizing antibody using these VLPs. First, the genome of HPV18 was cloned from a patient in Xiamen. It was used as template for PCR amplification of HPV18 L1 gene. The resultant DNA fragment was inserted into expression vector pTrxFus and expressed in Escherichia coli GI724. Second, L1 protein was purified by ammonium sulfate precipitation, ion-exchange chromatography and hydrophobic interaction chromatography; and the purified L1 was subjected to self-assembly to form VLPs with the removal of premixed reductant DTT. Finally, the size and morphology of these VLPs was investigated by Dynamic Light Scattering and Transmission Electronic Microscopy as 29.34 nm in hydrated radius and globular particles similar with native HPV18. The half effective dosage (ED50) and maximum level of neutralizing antibody elicitation were measured by vaccinations on mice, rabbit and goat using pseudovirus neutralization cell model. The results showed that the ED50 of HPV18 VLPs is 0.006 microg in mice, and the maximum titer of neutralizing antibody elicited in rabbit and goat is up to 10(7). As a conclusion, we can provide HPV18 VLPs with highly immunogenicity from prokaryote expression system, which may pave a new way for research and development of prophylactic vaccine for HPV18.